- Cyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection
-
Lee JY, Kim JH, Chae G, Lee BK, Ha KS, Kwon YG, Kim YM
- KMID: 946671
- Exp Mol Med.
- 2010 Jan;42(1):69-79.
- doi: 10.3858/emm.2010.42.1.008
This study was designed to investigate the effects of cAMP on immune regulation and apoptosis during acute rat cardiac allograft rejection. We found that the production of immune markers such... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation
-
Yang KS, Jeon H, Park Y, Jo IH, Kim JI, Moon IS, Choi BS, Park CW, Yang CW, Kim YS, Chung BH
- KMID: 1786104
- J Korean Med Sci.
- 2014 May;29(5):648-651.
- doi: 10.3346/jkms.2014.29.5.648
This study aimed to investigate the effect of bortezomib in the desensitization and treatment of acute antibody mediated rejection (AAMR) in kidney transplantation. Nine patients who received bortezomib therapy for... -
- CITED
-
- Close
- SHARE
-
- Close
- Complete Resolution of Posttransplant Lymphoproliferative Disorder (Diffuse Large B-cell Lymphoma) with Reduction of Immunosuppressive Therapy
-
Ryu HJ, Hahn JS, Kim YS, Park K, Yang WI, Lee JD
- KMID: 1734137
- Yonsei Med J.
- 2004 Jun;45(3):527-532.
- doi: 10.3349/ymj.2004.45.3.527
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation. PTLD is the disorder arising from the combined effects of Epstein-Barr virus associated lymphoid proliferation with the disruption of... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
-
Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH
- KMID: 2345894
- Yonsei Med J.
- 2015 Nov;56(6):1638-1642.
- doi: 10.3349/ymj.2015.56.6.1638
PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when... -
- CITED
-
- Close
- SHARE
-
- Close
